Elena Garralda Cabanas, MD, San Raffaele Scientific Institute, Milan, Italy, contemplates the potential role of tumor-infiltrating lymphocytes (TILs) in solid tumors, especially in melanoma. Cell therapies such as TILs have a lot of potential in terms of providing long term benefit, as demonstrated in the Phase III M14TIL trial (NCT02278887), which compared TIL therapy to ipilimumab in patients with melanoma. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.